Clinical Trial: PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07472140) titled 'PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer' on March 02.

Brief Summary: This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.

Study Start Date: July 01, 2025

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer Fallopian Tube Cancers Primary Peritoneal Cancer

Interve...